A prospective, multicenter, randomized, double-blind placebo-controlled trial on purified and specific Cytoplasmic pollen extract for hot flashes in breast cancer survivors
Bounous VE, Cipullo I, D'Alonzo M, Martella S, Franchi D
Published in Gynecological Endocrinology
Methodology
Prospective multicentre randomised double-blind placebo-controlled Italian trial of PureCyTonin cytoplasmic pollen extract versus placebo for three months in 39 breast cancer survivors with hot flashes.
Key Findings
The pollen extract group showed a reduction in hot flash number at three months versus baseline (p=0.02) with improved VAS ratings for intensity, sweating, irritability and fatigue, and a better total Menopause Rating Scale at one month.
Conclusions
Purified cytoplasmic pollen extract significantly reduced hot flash frequency in breast cancer survivors and was well tolerated.
Limitations
Very small sample (19 vs 20), short duration, within-group comparisons emphasised over between-group differences.
Supplements Studied
PureCyTonin significantly reduces HF number after 3 months of therapy in BCS and it is well-tolerated.
Outcomes Measured
PureCyTonin significantly reduces HF number after 3 months of therapy in BCS and it is well-tolerated.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.